LTC1849470I2 - Priešvėžinis vaistas, turintis alfa, alfa, alfa-trifluortimidino ir timidinfosforilazės inhibitorių - Google Patents

Priešvėžinis vaistas, turintis alfa, alfa, alfa-trifluortimidino ir timidinfosforilazės inhibitorių

Info

Publication number
LTC1849470I2
LTC1849470I2 LTPA2017024C LTC1849470I2 LT C1849470 I2 LTC1849470 I2 LT C1849470I2 LT PA2017024 C LTPA2017024 C LT PA2017024C LT C1849470 I2 LTC1849470 I2 LT C1849470I2
Authority
LT
Lithuania
Prior art keywords
alpha
trifluorothymidine
anticancer drug
drug containing
phosphorylase inhibitors
Prior art date
Application number
Other languages
English (en)
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC1849470(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of LTPA2017024I1 publication Critical patent/LTPA2017024I1/lt
Publication of LTC1849470I2 publication Critical patent/LTC1849470I2/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTPA2017024 2005-01-26 2017-07-28 Priešvėžinis vaistas, turintis alfa, alfa, alfa-trifluortimidino ir timidinfosforilazės inhibitorių LTC1849470I2 (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005165156 2005-06-06
PCT/JP2006/301097 WO2006080327A1 (ja) 2005-01-26 2006-01-25 α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Publications (2)

Publication Number Publication Date
LTPA2017024I1 LTPA2017024I1 (lt) 2017-08-10
LTC1849470I2 true LTC1849470I2 (lt) 2019-10-25

Family

ID=36740357

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP06712292.9T LT1849470T (lt) 2005-01-26 2006-01-25 Priešvėžinis vaistas, kurio sudėtyje yra alfa, alfa, alfa - trifluortimidinas ir timidinfosforilazės inhibitorius
LTPA2017024 LTC1849470I2 (lt) 2005-01-26 2017-07-28 Priešvėžinis vaistas, turintis alfa, alfa, alfa-trifluortimidino ir timidinfosforilazės inhibitorių

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP06712292.9T LT1849470T (lt) 2005-01-26 2006-01-25 Priešvėžinis vaistas, kurio sudėtyje yra alfa, alfa, alfa - trifluortimidinas ir timidinfosforilazės inhibitorius

Country Status (21)

Country Link
EP (1) EP1849470B2 (lt)
JP (1) JP5576591B2 (lt)
KR (1) KR101468216B1 (lt)
AU (1) AU2006209547C1 (lt)
BE (1) BE2017C028I2 (lt)
CA (1) CA2594713A1 (lt)
CY (2) CY2017029I2 (lt)
DK (1) DK1849470T4 (lt)
ES (1) ES2630002T5 (lt)
FI (1) FI1849470T4 (lt)
FR (1) FR17C1028I2 (lt)
HU (2) HUE033306T2 (lt)
LT (2) LT1849470T (lt)
LU (1) LUC00036I2 (lt)
NL (1) NL300889I2 (lt)
PL (1) PL1849470T5 (lt)
PT (1) PT1849470T (lt)
RU (1) RU2394581C2 (lt)
SI (1) SI1849470T2 (lt)
TW (1) TWI362265B (lt)
WO (1) WO2006080327A1 (lt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
JP5576591B2 (ja) 2005-01-26 2014-08-20 大鵬薬品工業株式会社 α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
PL2148676T3 (pl) 2007-04-25 2016-12-30 Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
MX2010012039A (es) 2008-05-09 2010-11-30 Gruenenthal Gmbh Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
EP2303283A2 (en) * 2008-05-15 2011-04-06 Katholieke Universiteit Leuven K.U. Leuven R&D Anti-cancer combination therapy
ES2428938T3 (es) 2009-07-22 2013-11-12 Grünenthal GmbH Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
BR112012001547A2 (pt) 2009-07-22 2016-03-08 Gruenenthal Gmbh forma de dosagem farmacêutica extrusada por fusão a quente
CN103179954A (zh) 2010-09-02 2013-06-26 格吕伦塔尔有限公司 包含阴离子聚合物的抗破碎剂型
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
PL2736497T3 (pl) 2011-07-29 2018-01-31 Gruenenthal Gmbh Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
NO2746404T3 (lt) 2011-08-16 2018-05-05
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
TWI526210B (zh) 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
AU2013233226B2 (en) 2012-03-14 2016-05-19 Nisshin Pharma Inc. Sulfur amino acid-containing composition
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
BR112014028420A2 (pt) * 2012-05-16 2017-09-19 Novartis Ag regime de dosagem para um inibidor de quinase pi-3
US9616081B2 (en) * 2013-03-27 2017-04-11 Taiho Pharmaceutical Co., Ltd. Antitumor agent including low-dose irinotecan hydrochloride hydrate
RS60958B1 (sr) * 2013-03-27 2020-11-30 Taiho Pharmaceutical Co Ltd Antitumorski agens koji uključuje irinotekan hidrohlorid hidrat
NZ714014A (en) * 2013-05-17 2017-06-30 Taiho Pharmaceutical Co Ltd Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased
WO2014191396A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
LT3042669T (lt) 2013-09-06 2023-06-26 Taiho Pharmaceutical Co., Ltd. Priešvėžinis agentas ir stipriklis su priešvėžiniu poveikiu
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US11612653B2 (en) * 2016-01-08 2023-03-28 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing immunomodulator, and antitumor effect potentiator
JP6882205B2 (ja) 2016-02-05 2021-06-02 大鵬薬品工業株式会社 重度腎機能障害を有する癌患者に対する治療方法
WO2019124544A1 (ja) 2017-12-22 2019-06-27 大鵬薬品工業株式会社 トリフルリジン及び／又はチピラシル由来の類縁物質の検出方法
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
US20260021045A1 (en) * 2024-07-17 2026-01-22 Jnd Therapeutics, Inc. Methods and formulations for treatment of liver cancer using trifluridine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0763529B1 (en) * 1995-03-29 2003-07-23 Taiho Pharmaceutical Company Limited Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
JP3088758B2 (ja) * 1996-09-24 2000-09-18 大鵬薬品工業株式会社 ウラシル誘導体を含有する癌転移抑制剤
JP5576591B2 (ja) 2005-01-26 2014-08-20 大鵬薬品工業株式会社 α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Also Published As

Publication number Publication date
FR17C1028I1 (lt) 2017-09-29
PL1849470T5 (pl) 2024-06-10
EP1849470A1 (en) 2007-10-31
ES2630002T3 (es) 2017-08-17
EP1849470B1 (en) 2017-06-21
KR101468216B1 (ko) 2014-12-03
EP1849470B2 (en) 2024-03-20
CY2017029I1 (el) 2018-02-14
CY2017029I2 (el) 2018-02-14
SI1849470T2 (sl) 2024-05-31
NL300889I2 (nl) 2018-01-16
PT1849470T (pt) 2017-09-22
PL1849470T3 (pl) 2017-11-30
SI1849470T1 (sl) 2017-10-30
AU2006209547B2 (en) 2011-05-26
TW200637562A (en) 2006-11-01
NL300889I1 (nl) 2017-08-14
LUC00036I2 (lt) 2017-12-01
KR20070104559A (ko) 2007-10-26
CY1119393T1 (el) 2018-02-14
JPWO2006080327A1 (ja) 2008-06-19
HUS1700032I1 (hu) 2017-09-28
ES2630002T5 (es) 2024-09-19
WO2006080327A1 (ja) 2006-08-03
DK1849470T3 (en) 2017-08-14
BE2017C028I2 (lt) 2025-09-10
LUC00036I1 (lt) 2017-10-02
LTPA2017024I1 (lt) 2017-08-10
HUE033306T2 (hu) 2017-11-28
JP5576591B2 (ja) 2014-08-20
EP1849470A4 (en) 2010-12-08
FI1849470T4 (fi) 2024-03-22
RU2394581C2 (ru) 2010-07-20
RU2007132181A (ru) 2009-03-10
AU2006209547A1 (en) 2006-08-03
AU2006209547C1 (en) 2022-04-07
LT1849470T (lt) 2017-07-25
FR17C1028I2 (fr) 2018-11-02
CA2594713A1 (en) 2006-08-03
TWI362265B (en) 2012-04-21
DK1849470T4 (en) 2024-04-02

Similar Documents

Publication Publication Date Title
LTC1849470I2 (lt) Priešvėžinis vaistas, turintis alfa, alfa, alfa-trifluortimidino ir timidinfosforilazės inhibitorių
NO343776B1 (no) Forbindelse som modulerer farmakokinetikkegenskaper til terapeutika, dens anvendelse i terapi og farmasøytisk sammensetning derav.
BRPI0815773A2 (pt) composto, e, medicamento.
DK2079485T3 (da) Phenylpropionamidforbindelser og anvendelsen deraf
IL195245A0 (en) Substituted prolinamides, production thereof and their use as drugs
IL194751A0 (en) Drugs and uses
DK2034015T3 (da) Immunstimulerende oligonucleotid og farmaceutisk anvendelse heraf
AP2008004533A0 (en) Pharmaceutical combination
DK1957073T3 (da) Lægemiddel
IL198236A0 (en) Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
GB0516069D0 (en) Pharmaceutical and use thereof
EP1902406A4 (en) BIOMETRIC DRUG CONTAINER
ZA200804666B (en) Pharmaceutical combination
BRPI0614413A2 (pt) composto, e, composição farmacêutica
EP1915988A4 (en) COMPRESSOR COMPRISING MULTIPLE SEGMENTS CONTAINING MEDICAMENTS
BRPI0614412A2 (pt) composto, e, composição farmacêutica
PL1954288T3 (pl) Pochodne amidyny i ich zastosowanie jako leków
DK1720557T3 (da) Hurtig-opløselig, smagsmaskeret tablet
AT501087A3 (de) Medizinisches winkelstück
DE602006017569D1 (de) Pharmazeutische kombinationen mit lamivudin, stavudin und nevirapin
FR2877129B1 (fr) Article de maquillage.
ITMO20050026U1 (it) La tavoletta dermopuntrice stimolante
ITMO20050310A1 (it) La tavoletta dermopuntrice stimolante
GB0500826D0 (en) Pharmaceutical use
GB0511347D0 (en) Medicine Prop